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Botswana has one of the highest rates of HIV infection in
the world, with 37.4% of adults infected in 2003 accord-
ing to UNAIDS. To address the problems of widespread
infections, the government of Botswana instituted aggres-
sive programs for the use of antiretroviral (ARV) drugs in
both chemoprophylaxis for pregnant women and HAART
therapy for treatment of clinical AIDS. At present, about
25% of AIDS patients receive HAART, and about 40% of
HIV positive pregnant women receive chemoprophylaxis.
After the country adopted an "opt out" policy for HIV test-
ing in early 2005, these numbers are rapidly rising. Both
the chemoprophylaxis regimen and the first line regimen
for AIDS, include nevirapine (NVP). This is likely to cause
problems with drug resistance when mothers with young
infants need therapy, as about half of the mothers who
receive NVP during labor reveal genotypic resistance when
analyzed. In a recent trial we showed that NVP given only
to newborn infants is as effective as when given to the
mother during labor and the newborn infant, at least
when used on a background of zidovudine (ZDV). This
may provide a mechanism to avoid the establishment of
NVP-resistance in HIV-positive mothers. HIV-1C, the sub-
type of southern Africa, shows higher rates of NVP-resist-
ance as compared to HIV-1A or HIV-1D.
Despite the potential for high levels of resistance, and
advanced stages of disease, AIDS patients were very suc-
cessfully treated with HAART. With initiation of drugs at
median plasma viral loads of about 400,000 and median
CD4 counts below 100, 87% of patients treated with
ZDV+ 3TC+ NVP had undetectable RNA at 24 weeks after
treatment, and 79% had undetectable RNA at 48 weeks.
CD4 numbers increased by 149 at 24 weeks and 204 by 48
weeks. ZDV and 3TC containing regimens gave lower rates
of viral resistance and less toxicity than regimens contain-
ing DDI and D4T.
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